title: Response to alemtuzumab in FIP1L1/PDGFRA-negative hypereosinophilic myocarditis on serial cardiac magnetic resonance imaging.
authors.affiliation: Division of Cardiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: Faisal F
authors.initials: FF
authors.lastname: Syed
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Bleeker
authors.forename: James
authors.initials: J
authors.lastname: Glockner
authors.forename: Animesh
authors.initials: A
authors.lastname: Pardanani
authors.forename: Leslie T
authors.initials: LT
authors.lastname: Cooper
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009205:Myocarditis / Q000188:drug therapy*; D015514:Oncogene Proteins, Fusion; D020796:Receptor, Platelet-Derived Growth Factor alpha; D039221:mRNA Cleavage and Polyadenylation Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D015514:Oncogene Proteins, Fusion; D039221:mRNA Cleavage and Polyadenylation Factors; D000074323:Alemtuzumab; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha